Synonyms: Ogsiveo® | PF-03084014 | PF3084014 | Z-3181
nirogacestat is an approved drug (FDA (2023))
Compound class:
Synthetic organic
Comment: Nirogacestat (PF-3084014) is compound 14f in [2] where it is described as a centrally active γ-secretase inhibitor. It is a reversible, non-competitive, and orally bioactive agent. It was proposed an an anti-tumour agent [1,3,11-12].
PF-3084014 was also reported as an inhibitor of the NOTCH signalling pathway which bolstered its oncology credentials [8,11], since NOTCH inhibition promotes cell cycle arrest and induces apoptosis in tumour cells. |
|
Classification | |
Compound class | Synthetic organic |
Approved drug? | Yes (FDA (2023)) |
IUPAC Name |
(2S)-2-[[(2S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl]amino]-N-[1-[1-(2,2-dimethylpropylamino)-2-methylpropan-2-yl]imidazol-4-yl]pentanamide |
International Nonproprietary Names | |
INN number | INN |
10404 | nirogacestat |
Synonyms |
Ogsiveo® | PF-03084014 | PF3084014 | Z-3181 |
Database Links | |
CAS Registry No. | 1290543-63-3 (source: WHO INN record) |
ChEMBL Ligand | CHEMBL1770916 |
GtoPdb PubChem SID | 223366079 |
PubChem CID | 46224413 |
RCSB PDB Ligand | O6U |
Search Google for chemical match using the InChIKey | VFCRKLWBYMDAED-REWPJTCUSA-N |
Search Google for chemicals with the same backbone | VFCRKLWBYMDAED |
Search PubMed clinical trials | nirogacestat |
Search PubMed titles | nirogacestat |
Search PubMed titles/abstracts | nirogacestat |
UniChem Compound Search for chemical match using the InChIKey | VFCRKLWBYMDAED-REWPJTCUSA-N |
UniChem Connectivity Search for chemical match using the InChIKey | VFCRKLWBYMDAED-REWPJTCUSA-N |